Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) EBIT (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed EBIT for 4 consecutive years, with -$27.5 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 57.97% to -$27.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$127.8 million through Dec 2025, up 41.2% year-over-year, with the annual reading at -$127.8 million for FY2025, 41.2% up from the prior year.
  • EBIT for Q4 2025 was -$27.5 million at Day One Biopharmaceuticals, down from -$24.3 million in the prior quarter.
  • The five-year high for EBIT was $29.6 million in Q3 2024, with the low at -$114.8 million in Q2 2024.
  • Average EBIT over 4 years is -$43.6 million, with a median of -$41.9 million recorded in 2022.
  • The sharpest move saw EBIT surged 157.61% in 2024, then plummeted 181.83% in 2025.
  • Over 4 years, EBIT stood at -$42.7 million in 2022, then tumbled by 39.24% to -$59.5 million in 2023, then dropped by 9.77% to -$65.3 million in 2024, then surged by 57.97% to -$27.5 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$27.5 million, -$24.3 million, and -$35.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.